North pharmaceutical company Locus Biosciences has acquired California - based EpiBiome for an undisclosed sum . Locus CEO Paul # ##me EpiBiome had developed " the world 's most effective automated platform for finding novel therapeutic phages " . It will support Locus ' use of CRISPR - resistant therapeutic therapeutics , developed to eliminate antibiotic resistant drugs , while avoiding beneficial bacteria in the body . Locus said the company will also help it in its work in developing phages aimed at treating patients with inflammatory bowel disease and colorectal cancer .
North Carolina company Locus Biosciences has acquired California-based EpiBiome for an undisclosed sum. Locus CEO Paul Garolfalo said EpiBiome had developed "the world's most effective automated platform for finding novel therapeutic phages". It will support Locus' use of CRISPR-based phage therapeutics, developed to eliminate antibiotic resistant drugs, while avoiding beneficial bacteria in the body. Locus said the acquisition will also help it in its work in developing phages aimed at treating patients with inflammatory bowel disease and colorectal cancer.